Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE

Classement en actions #31898
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Prix de l'action
$0.21483059
Dernière synchronisation: 2024-05-07
Capitalisation boursière
$11.13M
Changement (1 jour)
0.34%
Changement (1 an)
-0.36%
Pays
CA
Échange Antibe Therapeutics Inc. (ATE)

Catégorie

Healthcare
Historique des divisions d’actions pour Antibe Therapeutics Inc. (ATE)
L’action Antibe Therapeutics Inc. (symbole : ATE) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action ATE achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions ATE.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes
Entreprise Nombre de divisions d’actions Multiplicateur cumulatif Pays
9 x285
US
7 x127
IE
9 x162
US
2 x4
US
0 -
DE